Registration now open: A case by case review
of innovative and practical solutions for preventing
CLABSI
MISSISSAUGA, ON, March 27,
2023 /CNW/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical
technologies company, today announced the second expert-led webinar
in its CLABSI Conscious campaign, titled "Protecting CVADs from
Gross Contamination", to be held on Wednesday, March 29 at 1pm
EDT. Central line-associated blood stream infections
("CLABSI") often result from fluids and other substances that
contain bacteria and which end up in contact with a central venous
access device ("CVAD").
Amongst frontline shortages, and an increase in traveling
nurses, clinicians around the world are doubling down on their
efforts to reduce CLABSIs to protect vulnerable patients from a
devastating setback (at best), and at worst, a life-threatening
infection that results in death. Yet, CLABSIs are on the rise in
pediatric units across the US. The CDC (Centers for Disease Control
and Prevention) has reported a 47% increase in CLABSIs since the
outset of the COVID-19 pandemic.
In this webinar, Matthew Ostroff,
MSN, AGACNP, VABC, CPUI, a top pediatric vascular access
specialist, will address the current climate in healthcare, and
offer new solutions with seasoned expert guidance to target zero
CLABSIs. Webinar attendees will hear expert opinions related to
CLABSI conscious practices, and explore new technology designed to
help prevent CLABSIs by maintaining safety and consistency in the
NICU, PICU, and beyond.
Webinar Details
Title: Protecting CVADs from Gross Contamination
Presentation by:
Matthew
Ostroff, MSN, AGACNP, VABC, CPUI
Vascular Access Coordinator and Lead APN
- 20 Years Clinical Experience
- Internationally recognized Speaker, Vascular Access Expert,
Innovator, and Researcher
- Member of INS, AVA & WoCoVA
Date: Wednesday, March 29,
2023 at 1 – 2pm EDT / 10 –
11am PDT
Registration: https://covalon.webinargeek.com/protecting-cvads-from-gross-contamination-1
Hashtags: #CLABSI, #infectionprevention, #vascularaccess
For healthcare providers who are not able to attend the webinar
but are interested in learning more about Covalon's solutions,
visit www.covalon.com or follow Covalon on LinkedIn, Facebook,
Instagram or Twitter.
About Covalon
Covalon Technologies Ltd. is a patient-driven medical device
company, built on the relentless pursuit to help the most
vulnerable patients have a better chance at healing. Through a
strong portfolio of patented technologies and solutions for
advanced wound care, infection prevention, and medical device
coatings, we offer innovative, gentler, and more compassionate
options for patients to heal with less infections, less pain, and
better outcomes. Our solutions are designed for patients and made
for care providers. Covalon leverages its patented medical
technology platforms and expertise in two ways: (i) by developing
products that are sold under Covalon's name; and (ii) by developing
and commercializing medical products for other medical companies
under development and license contracts. The Company is listed on
the TSX Venture Exchange, having the symbol COV and trades on the
OTCQX Market under the symbol CVALF. To learn more about Covalon,
visit our website at www.covalon.com.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements
which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend", or variations of such words and
phrases or state that certain actions, events, or results "may",
"could", "would", "might", "will" or "will be taken", "occur", or
"be achieved". In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management's expectations,
estimates, and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the "Risks
and Uncertainties" section of our management's discussion and
analysis of financial condition and results of operations for the
year ended September 30, 2022, which
is available on the Company's profile at
www.sedar.com, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events, or
otherwise, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/covalon-presents-new-clabsi-conscious-series-webinar-protecting-cvads-from-gross-contamination-301781444.html
SOURCE Covalon Technologies Ltd.